Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study

 Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study

Urology San Antonio Collaborates with Anixa Biosciences on Ccheck Prostate Cancer Study

Shots:

  • Urology San Antonio joins Anixa’s ongoing Cchek prostate cancer study to advance Ccheck liquid biopsy technology toward commercialization
  • The collaboration will improve the care of patients with prostate cancer with the commercialization of the technology utilizing flow cytometry coupled with AI to detect cancer early, making a significant impact on the overall testing paradigm
  • Cchek is an early cancer detection technology act by measuring a patient’s immunological response to a malignancy, analyzing immune system cells in peripheral blood. The patient’s cancer status can be detected via simple blood draw eliminating the need for a biopsy with its expected commercial launch by the year-end 2019

Click here to­ read full press release/ article | Ref: PRNewswire | Image: Pharmaceutical Technology

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post